VTR

Ignore the 151x headline P/E — it's the wrong lens for a REIT. GAAP net income is suppressed by $1.38B of depreciation on a $27.6B real-estate book, which is why ROE screens at a meaningless 2.1%. The honest cash picture is operating cash flow of $1.65B (+23.8% YoY); adding D&A back to net income puts FFO near ~$1.6B, or roughly $3.4/share, so the stock trades at a more rational ~24x FFO — full, but not absurd for the asset class.

The business is genuinely improving. Revenue grew 18.5% to $5.83B, accelerating off a multi-year ramp ($3.83B→$4.13B→$4.50B→$4.92B→$5.83B), and the company climbed out of two straight years of GAAP losses (2022, 2023) to $262M net income. The MD&A makes the engine clear: the senior housing operating portfolio (SHOP) is now 49.4% of NOI ($1.18B of $2.39B), and management's stated strategy is 'profitable organic growth in senior housing' plus 'value-creating external growth' — a direct play on a 'large and growing aging population.' This is the right asset mix for the demographic decade ahead, and revenue durability looks high given long-dated healthcare real estate.